MARLBOROUGH, Mass., May 8,
2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ:
RXII) a biotechnology company developing the next generation of
immuno-oncology therapeutics based on its proprietary
self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced
today that it was granted a patent from the United States Patent
and Trademark Office (USPTO) for the methods of use of sd-rxRNAs
targeting Connective Tissue Growth Factor (CTGF) for the treatment
or prevention of fibrotic disorders, including skin fibrosis (USPTO
Patent #: 9,963,702 B2). This patent includes RXI-109 and its use
in dermal scarring, for which the safety and efficacy was shown in
a recent Phase 2 clinical trial with statistically significant
outcomes for improved visual appearance for RXI-109 treated scar
over control. The patent is set to expire in 2031.
Logo:
http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg
"Robust clinical data and strong IP are key elements to
successful pharmaceutical development and commercialization," said
Dr. Gerrit Dispersyn, Chief Development Officer of RXi
Pharmaceuticals. He added that, "Additional data on the results of
our recent clinical study with RXI-109 in dermal scarring will be
presented next week at the International Investigative Dermatology
Conference. These data, in combination with the granting of this
patent, supports RXi's ongoing discussions with potential partners
for our Dermatology Franchise, including RXI-109."
About RXi's Dermatology Franchise
RXi announced in January 2018 that it would
exclusively focus on developing the next generation of
immuno-oncology therapeutics based on its self-delivering RNAi
therapeutic platform. As such, it is actively seeking to
partner or out-license both its Dermatology and Ophthalmology
Franchises.
Each of these Franchises is comprised of a number of preclinical
and clinical-stage assets broadly covered by a robust intellectual
property estate. To obtain more information about these assets,
contact RXi's Director of Business Development, Dr. James
Cardia at jcardia@rxipharma.com
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company developing the next generation of
immuno-oncology therapeutics based on its self-delivering RNAi
(sd-rxRNA®) therapeutic platform. The Company's discovery and
research efforts are focused on developing sd-rxRNA therapeutic
compounds to be used with an Adoptive Cell Transfer (ACT) approach.
This process uses immune cells, such as T-lymphocytes that are
isolated from the patient or retrieved from allogeneic immune cell
banks, and then expanded and in some cases processed to express
tumor-binding receptors. Our approach introduces a new and
important step in ex-vivo processing of the immune
cells where sd-rxRNA is used to eliminate the expression of
immunosuppressive receptors or proteins from the therapeutic immune
cells, making them less sensitive to tumor resistance mechanisms
and thus improving their ability to destroy the tumor cells.
Essentially, we aim to maximize the power of our sd-rxRNA
therapeutic compounds by weaponizing therapeutic immune effector
cells to attack cancer and ultimately provide patients battling
terminal cancers with a powerful new treatment option that goes
beyond current treatment modalities.
For additional information, visit the Company's
website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our expectation regarding closing of the offering, our
ability to successfully develop RXI-109, Samcyprone™, RXI-762,
RXI-804 and our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact RXi Pharmaceuticals Corporation
Tamara McGrillen
Tel: +1 508-929-3646
Email: tmcgrillen@rxipharma.com
View original
content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-bolsters-strength-of-dermatology-intellectual-property-estate-following-granting-of-patent-from-uspto-300644758.html
SOURCE RXi Pharmaceuticals Corporation